Concepedia
Statistics
Publications
8
Citations
2K
H-Index
Active since
2012
Affiliations
Sarah Cannon(Current)
Cornell University
Northwestern University
Emory University
The University of Texas MD Anderson Cancer Center
Will Donnellan is an author at Sarah Cannon specializing in medicine, chemotherapy, and hematologic malignancy therapy.
Publications per year
2012–2022
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text
Medicine, Pharmacology, Pharmacotherapy +13
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein et al. · Blood · 2019 · 375 citations · Full text
Medicine, Hematology, Pharmacology +12
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Justin M. Watts, Maria R. Baer, Jay Yang et al. · The Lancet Haematology · 2022 · 117 citations · Full text
Medicine, Hematology, Pharmacology +15
Examining racial differences in diffuse large B-cell lymphoma presentation and survival
Christopher R. Flowers, Pareen J. Shenoy, Uma Borate et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 57 citations · Full text
Medicine, Hematology, Oncology +11
Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
Courtney D. DiNardo, Stéphane de Botton, Eytan M. Stein et al. · Blood · 2017 · 23 citations
Medicine, Hematology, Oncology +16
1–5 of 8